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A Comparison of the Treatment Recommendations for Neurogenic Lower Urinary Tract 
Dysfunction in the National Institute for Health and Care Excellence, European Association of 
Urology and International Consultations on Incontinence Guidelines. 
ABSTRACT: 
AIMS: Healthcare guidelines are an important vehicle in establishing up-to-date evidence based 
medicine (EBM) in clinical practice. Due to varying development processes, clinical guidelines created 
by different institutions can often contain contrasting recommendations. This can have implications 
for optimal and standardised patient care across management settings. 
METHODS: The similarities and differences of treatment recommendations made in the National 
Institute for Health and Care Excellence (NICE), The European Association of Urology (EAU) and the 
International Consultation on Continence (ICI) guidelines for neurogenic lower urinary tract 
dysfunction (NLUTD) were assessed. 
RESULTS: The guidelines generally agree on their approach to conservative management, including 
behavioural therapies and catheterisation techniques. There was discrepancy on the benefit of using 
an alpha blocker in NLUTD and bladder outlet obstruction (BOO) and administering Botulinum toxin A 
(Onabotulinum-A) in NLUTD. The highest degree of divergence was seen in recommendations for 
surgical treatments, where the EAU made gender-specific recommendations, and gave continent 
urinary diversion higher preference than given in the NICE and ICI guidelines. 
CONCLUSIONS: In the absence of high-quality clinical evidence, many of the recommendations made 
across all three guidelines are based on expert opinion. NICE, the EAU and ICI have similarities but 
they place differing emphasis on costs and expert opinion, which translated in notably different 
recommendations. It is evident that increased research efforts, possibly in the form of prospective 
registries, pragmatic trials and resource utilisation studies are necessary to improve the underlying 
evidence base for  NLUTD, and subsequently the strength and concordance of recommendations 
across guidelines. 
MAIN TEXT: 
BACKGROUND 
Disturbance to the normal micturition process emanating from neurological damage or disease is 
known as neurogenic lower urinary tract dysfunction (NLUTD). The underlying neurological disease 
differentiates NLUTD from those suffering from idiopathic overactive bladder (OAB). NLUTD 
encompasses a breadth of neurological aetiologies, including stroke, spinal cord injuries (SCI), multiple 
sclerosis (MS) and Parkinson’s disease (PD). Patients that fall under the umbrella term of NLUTD are 
notably unique in urological symptoms and risk profile due to differences in underlying condition 
(including stage and severity) and location of neurological lesion. 
There are myriad treatment options for the management of NLUTD, supported by a substantial 
evidence base. The evidence is however dominated by observational studies and clinical studies with 
weak methodological design. Clinical guidelines aid physicians in making optimal treatment choices 
through encapsulating the plethora of dynamic scientific research and expert opinion into easy to 
follow recommendations. The most prominent NLUTD guidelines are produced by the National 
Institute for Health and Care Excellence (NICE), the European Association of Urology (EAU) and the 
International Consultation on Continence (ICI). 1,2,3 
Due to variations in development processes, clinical guidelines by different institutions can often 
contain contrasting recommendations. This can be confusing for healthcare professionals and patients 
when devising management strategies, and can affect standardisation of care.4 To assess the 
concordance of prominent guidelines for NLUTD; we assessed the similarities and differences of 
treatment recommendations made in the NICE, EAU and ICI guidelines. 
GUIDELINES 
We included the three most prominent guidelines for NLUTD from recognised institutions within the 
UK, Europe and internationally. 
NICE provides evidence-based clinical care guidance for the UK National Health Service (NHS).5 The 
guidelines entitled ‘urinary incontinence related to neurological disease’ are applicable to adults and 
children. The guidelines are updated periodically, and the most recent update was in 2012. NICE uses 
a modified version of the Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) system to rate the quality of evidence and uses the wording of recommendations to reflect 
the strength of the recommendation.  
The EAU strives to improve urological practice, research and education across Europe.6 They provide 
guidelines on a wide range of urological topics, including for NLUTD. The guidelines are updated 
annually, with the most recent edition being in 2017. The EAU present levels and grades of 
recommendations using a modified version of the Oxford Centre for Evidence-based Medicine system 
(OCEBM 2009).  
The International Consultation on Urologic Disease (ICUD) is a non-governmental organisation 
registered with the World Health Organisation (WHO). The ICI is a sub-committee of the ICUD, tasked 
with developing recommendations with worldwide relevance for lower urinary tract dysfunction 
(LUTD).7 Their guidelines entitled ‘neurologic urinary and faecal incontinence’ are based on evidence 
and conclusions drawn at the sixth annual ICI conference. The ICI uses a modified version OCEBM 
2011. They provide evidence levels for conclusions drawn from the literature and grades for 
recommendations.  
RESULTS 
BEHAVIOURAL INTERVENTIONS 
Whilst no graded recommendations are made in the EAU guidelines, behavioural interventions are 
advocated in both the NICE and ICI guidelines, although recommendations are based on a lack of 
clinical evidence.  
NICE and the ICI broadly agree on their recommendations for individuals with cognitive impairment 
(table 1). All three guidelines agree on the use of pelvic floor muscle training (PFMT) in combination 
with electrical stimulation or biofeedback, however NICE only advocate this technique in SCI or MS, 
and the EAU recommend it only in MS patients (table 1). The ICI and EAU endorse expression 
techniques such as the Credé and Valsalva manoeuvres, only if proven urodynamically safe, however 
both guidelines also stress that the manoeuvres can be potentially hazardous.  
ORAL PHARMACOLOGICAL MANAGEMENT 
Antimuscarinics are the preferred pharmacological treatment for neurogenic detrusor overactivity 
(NDO); although NICE make a weaker recommendation for progressive brain conditions (table 2). All 
guidelines advise cautionary use of these drugs due to the increased possibility of adverse effects such 
as cognitive dysfunction, urinary tract infections (UTIs) and constipation. The ICI and NICE guidelines 
particularly express concern of use in patients with pre-existing cognitive impairment. The EAU 
suggests employing antimuscarinics in combinations in order to maximise outcomes (table 2).   
The ICI and EAU recommend α -blockers for bladder outlet obstruction (BOO) resistance. Conversely, 
α -blockers are recommended against in the NICE guidelines for bladder emptying problems, as they 
are deemed not cost-effective (table 2). 
MINIMALLY INVASIVE TREATMENTS 
The EAU recommends alternative (non-oral) routes of administration of antimuscarinic drugs. Both 
the ICI and NICE do not provide graded recommendations for alternative forms of antimuscarinic 
administration. 
On account of high-level evidence, the EAU and NICE advocate Onabotulinum-A in NDO as a 
consequence of SCI and MS (table 3). In contrast, the ICI recommends Onabotulinum-A for NDO 
indiscriminate of underlying neurological condition (table 3). The ICI again diverges from EAU and NICE 
when it recommends Onabotulinum-A for detrusor sphincter dyssynergia (DSD) in SCI (table 3).  
The ICI guidelines provide grade C/D recommendation for electrical neuromodulation techniques 
including, however both the EAU and ICI agree there are limited reports proving efficacy (table 3).  
CATHETERS AND APPLIANCES 
All guidelines recommend intermittent catheters (IC) over indwelling catheter (IDC) due to increased 
complications such as renal problems and bladder stones associated with the latter (table 4), though 
the ICI guidelines do not completely preclude its use (table 4). NICE also recognise that in some 
instances the choice of management technique is limited by what the patient can manage. 
When considering appliances, NICE recommend the use of catheter valves over drainage bags. The ICI 
and EAU guidelines advocate the use of condom catheters with a collection device in men (although 
the EAU do not provide a graded recommendation) (table 4).  
SURGICAL PROCEDURES 
All guidelines recommend augmentation using intestinal segment in refractory NDO (table 5). NICE 
consider augmentation to be more cost-effective than Onabotulinum-A in patients likely to benefit 
from treatment for more than 10 years.  
The EAU make gender specific recommendations for autologous sling use in SUI and artificial urinary 
sphincter (AUS) in neurogenic sphincter deficiency. NICE differ from the other guidelines when they 
only recommend AUS use after autologous sling procedures have failed, due to the high rates of re-
operation in ten years (table 5). The ICI make further recommendations for stress urinary incontinence 
(SUI) that are not covered by the other guidelines. They also present bladder neck closure as a last 
resort if all possible alternatives are unsuitable or have failed to relieve symptoms (table 5).  
According to the EAU, continent cystostomy is the preferable urinary diversion technique in 
refractory  NLUTD. Conversely, NICE only provide recommendations for ileal conduit diversion (table 
5).  
The ICI recommend urethral stenting or surgical sphincterotomy for patients with DSD, in whom IC is 
not an option. Sacral rhizotomy in conjunction with sacral anterior root stimulation (SARS) is given a 
graded recommendation by the ICI (and advocated in the EAU guidelines), in highly selected 
individuals (table 5). 
DISCUSSION 
Clinical guidelines are an important vehicle in establishing up-to-date evidence based medicine (EBM) 
in clinical practice. Adequate management in NLUTD offers benefits to the patient in terms of 
protection of the upper urinary tract, reduction in the rate of adverse sequelae and promotion of good 
quality of life (QoL).9 Additionally, unnecessary costs to the healthcare system can be avoided. Due to 
varying development processes, clinical guidelines can contain discordant treatment 
recommendations, which can cause unwarranted variation in care across practices. Despite many 
similarities, recommendations made in the NICE, EAU and ICI guidelines also diverged for some 
therapies. 
The guidelines generally agree on their approach to conservative management, including for 
behavioural therapies and catheterisation techniques. The recommendations for behavioural therapy 
were mostly based on expert opinion. NICE made their recommendations using evidence from the 
general elderly population, on the basis that no relevant evidence exists for neurological patients.  
When considering oral pharmacotherapy, all three guidelines place antimuscarinics as first line for 
NDO. Level 1 in the ICI evidence states tolterodine, propiverine, trospium and controlled-release 
oxybutynin have significantly less side effects compared to immediate release oxybutynin. Due to the 
lack of evidence differentiating antimuscarinics, NICE recommend balancing side effect profile with 
cost, rather than advocating the use of one drug over another.  
The ICI and NICE recommend further research into the use of newer antimuscarinics in NGB. It is 
interesting to note that although the ICI guidelines were published five years after the NICE guidelines; 
the same recommendation is made, indicating that little progress has been made in the way of this 
particular research. Despite highlighting the potential adverse effects of these drugs, none of the 
guidelines acknowledges the particular concern of use in progressive neurological conditions (e.g. PD 
and MS). Even if notable impairment does not already exist, the blood brain barrier (BBB) can become 
compromised, increasing the ability of antimuscarinics to bind to the M1 receptors in the brain and 
cause cognitive side effects.10,11,8  
The guidelines contain contrasting recommendations on alpha-blockers and Onabotulinum-A. 
Although some evidence exists demonstrating efficacy of alpha-blockers in NLUTD with BOO, the need 
for large randomised controlled trials (RCTs) remains.12 Despite this, alpha-blockers are advocated for 
use in the EAU and ICI guidelines. Onabotulinum-A is only licensed for NDO in SCI and MS due to the 
paucity of adequate research in other neurological conditions. The ICI guidelines still recommend 
Onabotulinum-A in all patients with NDO, regardless of underlying aetiology, thus it is evident that the 
EAU and NICE guidelines more accurately reflect the evaluated patient population. In the absence of 
high quality clinical evidence, recommendations for alpha-blockers and Onabotulinum-A were 
primarily reliant upon expert opinion. 
Disparities were most apparent in surgical treatments. One major difference between the EAU 
guidelines and the other guidelines were some gender-specific recommendations. Male autologous 
slings are relatively new interventions, with consequently less data supporting their use than female 
autologous slings.13 For this reason, use in males is not advocated in the EAU guidelines. On the other 
hand, AUS is not recommended in females, as physiological barriers introduce technical difficulties in 
implantation.14 All guidelines also differed in recommendations for urinary diversion. Whereas 
continent cystostomy is advocated in the EAU guidelines, NICE recommend ileal conduit diversion. 
The ICI do not advocate any one kind of diversion technique, which is perhaps most suitable, as 
superiority of one type of urinary diversion in terms of functionality and health related quality of life 
(HRQOL) has not yet been proven.15 The discrepancy between the NICE and EAU guidelines is again 
most likely because of differing expert opinion. 
Dissimilarities arose as a result of the differing interpretation of the underlying evidence base, varying 
considerations given to cost, and the weight given to expert opinion.  Since the ICI guidelines attempt 
worldwide relevance, they were most comprehensive. For example, the guidelines provide extensive 
recommendations for patients with SUI, considering treatments that were not assessed in the NICE or 
EAU guidelines. An advantage of the NICE guidelines was the well-integrated economic evaluation, 
which aims to improve national healthcare efficiency in the UK. As a result, certain recommendations 
diverged from what is recommended by the EAU and ICI, for example, the option to introduce bladder 
augmentation earlier than Onabotulinum-A in the treatment pathway for a subset of patients. Due to 
their broad country remit, cost assessment and/or consideration of resource utilisation is not possible 
for the EAU and ICI guidelines. The EAU guidelines were adequately detailed, and considered a broad 
range of treatments, however they lacked graded recommendations for behavioural management. 
In the absence of high-quality clinical evidence, many of the recommendations made across all three 
guidelines are based on expert opinion. In the EBM hierarchy, expert opinion is assigned the lowest 
level, as it can be subject to bias. At present, much of the clinical evidence that does exist for NLUTD 
focuses on SCI and MS, which may not be generalizable to the wider neuro-urological patient 
population, especially progressive neurological conditions.16 Filling the research gap is not easy, as 
conducting RCTs in the vulnerable NLUTD population can be impractical. In order to strengthen 
recommendations, increased research effort should be focused on collecting prospective registries or 
conducting pragmatic trials at centres managing a diverse range of neurological conditions. 
CONCLUSIONS 
NICE, the EAU and ICI guidelines are quite similar, but they do provide differing emphasis on costs and 
expert opinion, which translated in notably different recommendations. This is not surprising in the 
absence of high-quality clinical evidence for NLUTD. It is evident that increased research efforts are 
necessary to improve the underlying evidence base for NLUTD, and subsequently the strength and 
concordance of recommendations across guidelines. This will enhance the care that NLUTD receive, 
and ultimately improve patient outcomes. In addition to this, integrating cost-effectiveness analyses 
may improve efficiencies.   
TABLE LEGENDS 
Table 1: Behavioural management recommendations for NLUTD in the National Institute of Health 
and Care Excellence, European Association of Urology, and the International Consultations on 
Incontinence guidelines 
 
Table 2: Oral pharmacotherapy recommendations for NLUTD in the National Institute of Health and 
Care Excellence, European Association of Urology, and the International Consultations on 
Incontinence guidelines 
 
Table 3: Minimally invasive treatment recommendations for NLUTD in the National Institute of 
Health and Care Excellence, European Association of Urology, and the International Consultations on 
Incontinence guidelines 
 
Table 4: Catheter and appliance recommendations for NLUTD in the National Institute of Health and 
Care Excellence, European Association of Urology, and the International Consultations on 
Incontinence guidelines 
 
Table 5: Surgical procedure recommendations for NLUTD in the National Institute of Health and Care 
Excellence, European Association of Urology, and the International Consultations on Incontinence 
guidelines 
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